NEWS

Jul 24, 2026

PCAC Meeting Vote Summary

SSRP Institute

SSRP Institute

BREAKING NEWS

JULY 24, 2026 - The Pharmacy Compounding Advisory Committee (PCAC) has completed its July session, voting on several peptide bulk drug substances for potential inclusion on the FDA’s 503A Bulks List.
Recommended FOR inclusion: (Yes-No)
• BPC-157 (8–6)
• KPV (8–6)
• TB-500 (8–6)
• MOTS-c (7–5)
• Epitalon (7–4)
• Semax (8–5)
Recommended AGAINST inclusion: (Yes-No)
• DSIP (6–7)

What happens next? These votes are advisory recommendations only. The FDA will now review the committee’s recommendations alongside the scientific record, public comments, and other regulatory considerations before making a final decision on whether these bulk drug substances will be included on the 503A Bulks List.

Note: Peptide names refer to all related bulk drug substances.

Learn More

Click here to learn more about the July 2026 PCAC meetings. For future updates like this, education, training, and support, explore what the SSRP Community has to offer.

RELATED RESOURCES

Continue exploring related topics.

VIDEO

Cellular Medicine Mondays

Oct 12, 2026

Ep. 109 - Anti-Ageing Mini Mastermind Part 2

Preview only

Journal Club – Episode 109

Anti-Aging Mini Mastermind Part 2

In Part 2 of our Anti-Aging Mini Mastermind series, Dr. Seeds explores how PGE2 signaling and cellular metabolism influence inflammation, cognitive function, and aging, connecting foundational research to emerging discoveries in immunometabolism. (2026 Article) (2021 Article)

Preview Only — Become a member for full access

William Seeds, MD

EP2, Tissue-Resident Macrophages, and a New Mechanism of Organ Aging

William Seeds, MD Oct 8, 2026

EP2, Tissue-Resident Macrophages, and a New Mechanism of Organ Aging

Revisiting a Journal Club Article, “Restored clearance of senescent neutrophils by tissue-resident macrophages limits organ aging.” Science. 2026 Why This Paper Matters Most of the senescence conversation over the past decade has centered on a familiar cast: senescent fibroblasts, endothelial cells, adipocytes, and the drugs designed to clear them. This paper, which I discuss in […]

VIDEO

Cellular Medicine Mondays

Oct 5, 2026

Ep. 108 - Dr. Seeds’ Office Hours

Preview only

Dr. Seeds’ Office Hours – Episode 108

Dr. Seeds’ Office Hours – Episode 108

Questions Answered:
1. ARA-290 for Post Op 47yo Male [0:53]
2. Cold Therapy and the Wim Hof Method [17:06]

Preview Only — Become a member for full access

Healthgevity Introduces hydraCELL+™, Featuring Formulation IP Developed by the Seeds Foundation for Cellular Research

Healthgevity Introduces hydraCELL+™, Featuring Formulation IP Developed by the Seeds Foundation for Cellular Research

BREAKING NEWS INTERLAKEN, N.J., [October 2, 2026] — Healthgevity, a practitioner-focused precision longevity nutrition company, announced the launch of hydraCELL+™, a cellular hydration and muscle-support formula built on proprietary formulation IP developed through the Seeds Foundation for Cellular Research and licensed to Healthgevity. The formula reflects the cellular medicine approach advanced by William Seeds, MD, and […]

VIDEO

Cellular Medicine Mondays

Sep 28, 2026

Ep. 107 - Anti-Ageing Mini Mastermind Part 1

Preview only

Journal Club – Episode 107

Mini Anti-Aging Mastermind Part 1: Restored clearance of senescent neutrophils by tissue-resident macrophages limits organ aging

Part 1 of a special Mini Anti-Aging Mastermind inspired by the recent Science article exploring how impaired clearance of senescent neutrophils may contribute to age-related organ decline. Dr. Seeds begins breaking down the cellular mechanisms behind the research and what they reveal about the biology of aging. (Article Link)

Preview Only — Become a member for full access

William Seeds, MD

The Future of Regenerative Medicine May Begin with a Hair Follicle

William Seeds, MD Sep 23, 2026

The Future of Regenerative Medicine May Begin with a Hair Follicle

Why a Plucked Hair Follicle May Matter to the Future of Regenerative Medicine In this article, I return to a study that I discussed in a July Journal Club post. The study, published in Cells in 2024, investigated whether cells obtained from plucked, cryopreserved human hair follicles could be reprogrammed into induced pluripotent stem cells […]

Certification Certification

Peptide Therapy Certification 2026

Peptide Therapy Certification 2026

The SSRP Peptide Therapy Certification course gives clinicians, researchers, and other healthcare providers a working method for applying Cellular Medicine principles to patient care through clinical peptide therapy. Across 19 faculty-led lessons, Dr. William Seeds and SSRP faculty, including Siobhan...

19 Lessons

15 hrs 43 min

VIDEO

Cellular Medicine Mondays

Sep 21, 2026

Ep. 106 - Peptide Support After Transplant: What to Consider First

Preview only

Dissecting Protocols – Episode 106

Peptide Support After Transplant: What to Consider First

Dr. Seeds explores how to protect graft integrity and identify the right cellular targets before considering peptide support in a patient six years post liver transplant.

Preview Only — Become a member for full access

In Case You Missed it: FDA Approves Mounjaro (tirzepatide) for CVD

In Case You Missed it: FDA Approves Mounjaro (tirzepatide) for CVD

HEADLINE SCIENCE [Sept 14, 2026] – On August 28, 2026, the FDA expanded the indication for Mounjaro (tirzepatide), approving the dual GIP/GLP-1 receptor agonist to reduce the risk of major adverse cardiovascular events—including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke—in adults with type 2 diabetes at high cardiovascular risk. The decision makes tirzepatide the […]

Peptide Therapy Certification 2027

Four Seasons Resort Orlando at Walt Disney World, FL

COMING SOON

Peptide Therapy Certification 2027

COMING SOON